Ifg Advisory, LLC Neurocrine Biosciences Inc Transaction History

Ifg Advisory, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $199,602 - $266,187	-2,506 Closed	0 $0
Q3 2021 Oct 12, 2021	BUY	$86.18 - $99.03 $2,843 - $3,267	33 Added 1.33%	2,506 $240,000
Q2 2021 Jul 21, 2021	BUY	$89.43 - $102.27 $221,160 - $252,913	2,473 New	2,473 $240,000
Q4 2020 Feb 08, 2021	SELL	$86.91 - $108.33 $196,764 - $245,259	-2,264 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$96.16 - $135.15 $3,365 - $4,730	35 Added 1.57%	2,264 $217,000
Q2 2020 Aug 10, 2020	SELL	$85.09 - $130.36 $8,509 - $13,036	-100 Reduced 4.29%	2,229 $271,000
Q1 2020 May 11, 2020	SELL	$75.11 - $113.76 $171,100 - $259,145	-2,278 Reduced 49.45%	2,329 $201,000
Q4 2019 Feb 07, 2020	BUY	$86.8 - $118.57 $399,887 - $546,251	4,607 New	4,607 $495,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Ifg Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Ifg Advisory, LLC with notifications on news.